Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53 fl/+; Pdx1-Cre (KPC) pancreatic cancer model
M. H. Uddin, A. Aboukameel, Y. Li, H. Y. Khan, R. E. Sexton, S. Bannoura, G. Dyson, M. N. Al-Hallak, Y. Mzannar, A. Mohamed, Y. Landesman, S. Kim, R. Beydoun, R. M. Mohammad, A. F. Shields, A. S. Azmi
This study investigates the synergy between XPO1 inhibitor selinexor and gemcitabine-nab-paclitaxel in pancreatic cancer using cellular and mouse models, showing improved survival and molecular changes.
bioRxiv · Mar 8, 2022 · PreprintCancer Biology